Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax-Obinutuzumab in the Randomized Phase 3 CRISTALLO Trial
Paolo Sportoletti(University of Perugia), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Rosemary Harrup(University of Tasmania), Yanwen Jiang, Oscar Cazares, Franck Morschhauser(Centre Hospitalier Universitaire de Lille), Simona Barlera, Luca Laurenti(Fondazione Roma), Michelle Boyer(Amgen (United States)), Roberto Marasca(University of Modena and Reggio Emilia), Marcus Lefebure(Peter MacCallum Cancer Centre), Stephen P. Mulligan(Royal North Shore Hospital), Emmanuelle Ferrant(Hôpital Lyon Sud), Stephen Opat(Monash Health), Adalberto Ibatici(Ospedale Policlinico San Martino), Luis Felipe Casado Montero(Complejo Hospitalario Universitario de Toledo)
Cited by 0
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907